CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

被引：35

作者：

Petrioli, Roberto ^{[1
]}

Licchetta, Antonella ^{[1
]}

Roviello, Giandomenico ^{[1
]}

Pascucci, Alessandra ^{[1
]}

Francini, Edoardo ^{[1
]}

Bargagli, Gianluca ^{[1
]}

Conca, Raffaele ^{[1
]}

Miano, Salvatora Tindara ^{[1
]}

Marzocca, Giuseppe ^{[2
]}

Francini, Guido ^{[1
]}

机构：

[1] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy

[2] Univ Siena, Dept Gen Surg, I-53100 Siena, Italy

来源：

CANCER INVESTIGATION | 2012年 / 30卷 / 01期

关键词：

Capecitabine; CEA; CA19.9; Colorectal cancer; Bevacizumab; Oxaliplatin; Tumor markers; CAPECITABINE PLUS OXALIPLATIN; PHASE-II TRIAL; CARCINOEMBRYONIC ANTIGEN; 1ST-LINE THERAPY; TUMOR-MARKERS; ADENOCARCINOMA; MULTICENTER; SURVIVAL; FOLFOX-4; STAGE;

D O I：

10.3109/07357907.2011.629380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.

引用

页码：65 / 71

页数：7

共 50 条

[31] MGMT −535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
Jee Hyun Park
Nung Soo Kim
Jae Yong Park
Yee Soo Chae
Jong Gwang Kim
Sang Kyun Sohn
Joon Ho Moon
Byung Woog Kang
Hun Mo Ryoo
Sung Hwa Bae
Gyu Seog Choi
Soo-Han Jun
Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1135 - 1142
[32] Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study
Kato, Shunsuke
Imai, Hiroo
Gamoh, Makio
Takahata, Takenori
Ohori, Hisatsugu
Yasuda, Katsuhiro
Niitani, Tomohito
Murakawa, Yasuko
Amagai, Kenji
Isobe, Hideki
Shindo, Yoshiaki
Kuroki, Michio
Sakamoto, Yasuhiro
Shimodaira, Hideki
Yoshioka, Takashi
Ishioka, Chikashi
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 245 (01) : 21 - 28
[33] Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer
Cazeneuve, Nicolas
Bouche, Olivier
Leger, Julie
Borg, Christophe
Labbe-Devilliers, Catherine
Lucidarme, Olivier
Tasu, Jean-Pierre
Manfredi, Sylvain
Aube, Christophe
Trillaud, Herve
Manzoni, Philippe
Marcus, Claude
Terrebonne, Eric
Douillard, Jean -Yves
Chautard, Romain
Lobet, Sarah
Bleuzen, Aurore
Lecomte, Thierry
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
[34] Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
Liu, Yingmiao
Starr, Mark D.
Bulusu, Anuradha
Pang, Herbert
Wong, Nan Soon
Honeycutt, Wanda
Amara, Anthony
Hurwitz, Herbert I.
Nixon, Andrew B.
CANCER MEDICINE, 2013, 2 (02): : 234 - 242
[35] Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy
Michl, M.
Koch, J.
Laubender, R. P.
Modest, D. P.
Giessen, C.
Schulz, Ch.
Heinemann, V.
TUMOR BIOLOGY, 2014, 35 (10) : 10121 - 10127
[36] Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
Chibaudel, Benoist
Bonnetain, Franck
Tournigand, Christophe
Bengrine-Lefevre, Leila
Teixeira, Luis
Artru, Pascal
Desrame, Jerome
Larsen, Annette K.
Andre, Thierry
Louvet, Christophe
de Gramont, Aimery
ONCOLOGIST, 2011, 16 (09) : 1228 - 1238
[37] The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients
Knijn, N.
Tol, J.
Koopman, M.
Werter, M. J. B. P.
Imholz, A. L. T.
Valster, F. A. A.
Mol, L.
Vincent, A. D.
Teerenstra, S.
Punt, C. J. A.
EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) : 369 - 374
[38] MGMT-535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
Park, Jee Hyun
Kim, Nung Soo
Park, Jae Yong
Chae, Yee Soo
Kim, Jong Gwang
Sohn, Sang Kyun
Moon, Joon Ho
Kang, Byung Woog
Ryoo, Hun Mo
Bae, Sung Hwa
Choi, Gyu Seog
Jun, Soo-Han
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1135 - 1142
[39] Geriatric 8 score as a prognostic factor of the efficacy and safety of oxaliplatin-based chemotherapy in elderly patients with metastatic colorectal cancer
Koki Hara
Wakana Chikaishi
Yunami Yamada
Hironori Fujii
Jesse Yu Tajima
Hirotoshi Iihara
Akitaka Makiyama
Daichi Watanabe
Koichi Ohata
Chiemi Hirose
Ryo Kobayashi
Akio Suzuki
Nobuhisa Matsuhashi
International Journal of Colorectal Disease, 40 (1)
[40] Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
Ribero, Dario
Wang, Huamin
Donadon, Matteo
Zorzi, Daria
Thomas, Melanie B.
Eng, Cathy
Chang, David Z.
Curley, Steven A.
Abdalla, Eddie K.
Ellis, Lee M.
Vauthey, Jean-Nicolas
CANCER, 2007, 110 (12) : 2761 - 2767

← 1 2 3 4 5 →